Epic Sciences to present at UPS Global Healthcare Conference.
Epic Sciences, Inc. (“Epic”), a private biotech company that designs and develops diagnostics to personalize and advance the treatment and management of cancer, announced today that Michael Rodriguez, chief financial officer, will present at the UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 10:00 a.m. EDT. The conference will be held at the Sheraton New York Times Square Hotel in New York.
Epic is developing highly sensitive and informative diagnostic tests to rapidly quantify the proteomic and genomic changes that occur over time during the course of a patient’s cancer. Following a simple blood draw, Epic’s “no cell left behind” platform can detect all categories of circulating tumor cells (CTCs) in the blood, whereas other technologies rely on size or surface marker parameters and can “miss” CTCs critical to delivering a comprehensive view of cancer heterogeneity. Epic also recently announced that their platform technology is compatible with single cell genomic and proteomic analysis, enabling a further level of precision to detect early signs of drug resistance that could influence therapy selection, including the use of combination therapies.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., firstname.lastname@example.org,+1.858.344.8091